TNFRSF9 and neoplasm: This study concluded that the 4-1BB costimulatory molecule improved selectivity for higher tumor antigen concentrations and tumor-killing ability, therefore proving the clinical significance of costimulation for the making of an optimal CAR-T cell therapy regimen after analyzing the costimulation activity of both CD 28 and 4-1BB [63].